Kymera Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Kymera Therapeutics (KYMR).

Price Target Range — 12 Quarters

Analyst Consensus — 24 Analysts

21Buy

3Hold

Consensus RatingBuy# Analysts24Avg. Consensus PT$113Upside to Avg. PT+1.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 22, 2026	Stifel	Alex Thompson	PT Raise	Buy	$132→$152
Sep 14, 2026	B of A Securities	Tazeen Ahmad	PT Raise	Buy	$123→$144
Sep 10, 2026	Wolfe Research	Andy Chen	Upgrade	Peer Perform→Outperform	—
Aug 31, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$135→$170
Aug 27, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$116→$151
Aug 6, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$133→$139
Jul 30, 2026	Deutsche Bank	David Hoang	Initiate	Hold	$120
Jul 28, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$125→$135
Jul 16, 2026	Mizuho	Joseph Catanzaro	PT Raise	Outperform	$120→$140
Jul 13, 2026	RBC Capital	Brian Abrahams	Downgrade	Outperform→Sector Perform	$106→$115
Jun 30, 2026	B of A Securities	Tazeen Ahmad	PT Raise	Buy	$110→$125
Jun 29, 2026	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$116→$136
Jun 29, 2026	B. Riley Securities	Kalpit Patel	PT Raise	Buy	$117→$155
Jun 26, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$106→$129
Jun 25, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$134
May 6, 2026	Canaccord Genuity	Edward Nash	Initiate	Buy	$106
Mar 16, 2026	Jefferies	Faisal Khurshid	Assumes	Buy	$122→$110
Mar 3, 2026	UBS	David Dai	PT Raise	Buy	$90→$128
Mar 2, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$110→$120
Mar 2, 2026	Stephens & Co.	Sudan Loganathan	PT Raise	Overweight	$95→$100

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Stifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152

Stifel analyst Alex Thompson maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $132 to $152.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144

B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $123 to $144.

Benzinga Newsdesk

PRO
Wolfe Research Upgrades Kymera Therapeutics to Outperform

Wolfe Research analyst Andy Chen upgrades Kymera Therapeutics (NASDAQ:KYMR) from Peer Perform to Outperform.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $170

Guggenheim analyst Brad Canino maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $135 to $170.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Kymera Therapeutics, Raises Price Target to $151

Wells Fargo analyst Derek Archila maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $116 to $151.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139

Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $133 to $139.

Benzinga Newsdesk

Kymera Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Kymera Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Stifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152

PRO
B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144

PRO
Wolfe Research Upgrades Kymera Therapeutics to Outperform

PRO
Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $170

PRO
Wells Fargo Maintains Overweight on Kymera Therapeutics, Raises Price Target to $151

PRO
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139

People Also Watch

People Also Watch

Kymera Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Kymera Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROStifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152

PROB of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144

PROWolfe Research Upgrades Kymera Therapeutics to Outperform

PROGuggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $170

PROWells Fargo Maintains Overweight on Kymera Therapeutics, Raises Price Target to $151

PROBarclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139

People Also Watch

People Also Watch

PRO
Stifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152

PRO
B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144

PRO
Wolfe Research Upgrades Kymera Therapeutics to Outperform

PRO
Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $170

PRO
Wells Fargo Maintains Overweight on Kymera Therapeutics, Raises Price Target to $151

PRO
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139